2025 Q4 -tulosraportti
89 päivää sitten
‧39 min
Tarjoustasot
Spotlight Stock Market DK
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 428 | NRD | AVA | ||
| 1 025 | NRD | AVA | ||
| 475 | NRD | DDB | ||
| 1 500 | NRD | NRD | ||
| 1 115 | NRD | SSWM |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Välittäjätilasto
Ostaneet eniten
| Välittäjä | Ostettu | Myyty | Netto | Sisäinen |
|---|---|---|---|---|
| Nordnet Bank AB | 15 709 | 7 798 | +7 911 | 3 769 |
| Danske Bank A/S | 4 324 | 975 | +3 349 | 0 |
| Skandinaviska Enskilda Banken AB | 320 | 0 | +320 | 0 |
| Carnegie Investment Bank AB | 210 | 0 | +210 | 0 |
| SSW Market Making GmbH | 1 579 | 4 810 | −3 231 | 0 |
| Avanza Bank AB | 1 308 | 4 693 | −3 385 | 0 |
Myyneet eniten
| Välittäjä | Ostettu | Myyty | Netto | Sisäinen |
|---|---|---|---|---|
| Nordea Bank Abp | 4 671 | 9 845 | −5 174 | 1 543 |
| Avanza Bank AB | 1 308 | 4 693 | −3 385 | 0 |
| SSW Market Making GmbH | 1 579 | 4 810 | −3 231 | 0 |
| Carnegie Investment Bank AB | 210 | 0 | +210 | 0 |
| Skandinaviska Enskilda Banken AB | 320 | 0 | +320 | 0 |
| Danske Bank A/S | 4 324 | 975 | +3 349 | 0 |
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q1 -tulosraportti 29.5. | 3 päivää |
| Menneet tapahtumat | ||
|---|---|---|
2025 Q4 -tulosraportti 26.2. | ||
2025 Q3 -tulosraportti 1.12.2025 | ||
2025 Q2 -tulosraportti 28.8.2025 | ||
2025 Q1 -tulosraportti 25.4.2025 | ||
2024 Q4 -tulosraportti 27.2.2025 |
Asiakkaat katsoivat myös
Foorumi
Liity keskusteluun Nordnet Socialissa
Kirjaudu
·1 päivä sittenWhat do people say - what are your expectations or hopes regarding the earnings report - a big increase, a smaller decrease or something else???
·2 päivää sittenExciting
·1 päivä sitten · MuokattuWell, in principle, anything is possible. And when we don't have exact knowledge, it must rely on probabilities. So my 'certainty'= 99.999% This is primarily because HCA's Friday meeting is a regulatory necessity, held to give the market an update before the international spotlight turns on SNMMI, where Andreas presents on Tuesday. Had the data been bad or delayed, this meeting would never have been arranged the day before the conference starts..! That would be shooting oneself in the foot. If data is delayed, they would have had ample time to announce it to the market, which they would also be obliged to do. If data is not good enough to confirm that Curasight has a real theranostics-platform, which consists of both the diagnostic AND the therapeutic part, then it would be pure madness for Andreas to participate.. And SNMMI would never invite a top-tier researcher if his own flagship (uTREAT) had just proven to fail or deliver poor results three days prior! That would destroy both the conference's and Andreas' international credibility and reputation. So no, I find it VERY difficult to envision those two scenarios at Friday's HCA meeting. (but I reserve the right to the 0.001%)
·17 t sittenCurasight is accustomed to presenting their quarterly report in collaboration with HC Andersen Capital, so I imagine it will be a non event, where they (again) emphasize that everything is going according to plan. Finally, there's a Q&A session from the investors, where Ulrich and Andreas confidently repeat that everything looks rosy. Neither more nor less...which is also quite sufficient... :)- ·22.5.CURIUM AGREEMENT CHANGES EVERYTHING FOR CURASIGHT ☢️🔥 The partnership agreement with Curium gives Curasight direct access to existing global radiopharma infrastructure. Curium contributes not only with capital, but also with regulatory experience, global commercialization as well as production and distribution. The agreement includes milestone payments of up to 70 mio USD and double-digit royalties. In addition, Curium finances the entire uTRACE Phase II-program. Curium has the largest ownership stake in Curasight at 20%. This sends a significant signal about how much potential they see in the platform. The agreement with Curium is a huge advantage because Curasight does not start from scratch! 🔥 They are already directly connected to an existing global setup within isotopes, production, GMP, regulatory processes and distribution - something that takes many years and enormous investments to build up. And that is precisely what the market is increasingly starting to see. Theranostics is no longer just about strong biology and clinical data. In radiopharma, infrastructure has become at least as important. Isotopes are produced in relatively few places in the world, decay quickly and must be produced, transported and delivered almost in real-time. The entire value chain is complex, expensive and extremely difficult to scale quickly. BIG PHARMA POSITIONS ITSELF AGGRESSIVELY ☢️ The radiopharma market is expected to grow massively in the coming 5-10 years, and infrastructure can potentially become a real bottleneck. So strong data is therefore not enough if one cannot simultaneously produce and deliver the treatments globally. Already now, Novartis has started to experience capacity and delivery problems with both Pluvicto and Lutathera. That says a lot about how pressured the market is already starting to become. That is also why Big Pharma and the largest radiopharma companies are positioning themselves so aggressively right now. The battle is no longer just about who has the best data. RADIOPHARMA GOES FROM “SCIENCE” TO “INDUSTRIAL WAR” 🏭 The battle is not just about who has the best data. It is also about who can most quickly secure isotopes, production and global scaling. And this is precisely where the Curium agreement becomes so important. Curasight does not just get a partner. They get access to a large existing industrial engine in a market where infrastructure will probably become a major bottleneck in the coming years. This makes the platform significantly more attractive because a potential partner or buyer does not have to start building the entire infrastructure from scratch. As the theranostics market grows, it becomes crucial who can industrialize and scale globally. Big Pharma does not only get access to the uPAR platform and the data. They also get access to an existing setup for production, isotopes and global distribution from day one! And precisely that fact makes Curasight much more attractive in a future partnership or acquisition scenario! 🎯
- ·22.5.A minor detail, but Curasight has updated their "About us" subpage: The wording is more commercially oriented and emphasizes Utreat as Next-Gen. https://www.curasight.com/about-us/ (for comparison; the "About us" subpage from February 2026: https://web.archive.org/web/20260207020421/https://www.curasight.com/about-us/ Can this be read as optimization in connection with the upcoming SNMMI conference?·3 päivää sitten · MuokattuThey are redefining themselves as a clinical radiopharma platform with a theranostics focus! Great, we are truly on the right track! It will be interesting to see if, in connection with the Q1 report next week, which is a couple of days before the SNMMI conference, an FBM comes, so Andreas can talk about new uTREAT data at SNMMI. I find it very difficult to see Andreas going on the big international stage with old data!
·3 päivää sittenI asked Ulrich on April 16th at the investor seminar if there would be ongoing data from uTreat before they release Topline results. And the answer was that they expected an update before Topline. So it could actually be quite likely and good timing here before the conference.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
2025 Q4 -tulosraportti
89 päivää sitten
‧39 min
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Foorumi
Liity keskusteluun Nordnet Socialissa
Kirjaudu
- ·1 päivä sittenWhat do people say - what are your expectations or hopes regarding the earnings report - a big increase, a smaller decrease or something else???
- ·2 päivää sittenExciting·1 päivä sitten · MuokattuWell, in principle, anything is possible. And when we don't have exact knowledge, it must rely on probabilities. So my 'certainty'= 99.999% This is primarily because HCA's Friday meeting is a regulatory necessity, held to give the market an update before the international spotlight turns on SNMMI, where Andreas presents on Tuesday. Had the data been bad or delayed, this meeting would never have been arranged the day before the conference starts..! That would be shooting oneself in the foot. If data is delayed, they would have had ample time to announce it to the market, which they would also be obliged to do. If data is not good enough to confirm that Curasight has a real theranostics-platform, which consists of both the diagnostic AND the therapeutic part, then it would be pure madness for Andreas to participate.. And SNMMI would never invite a top-tier researcher if his own flagship (uTREAT) had just proven to fail or deliver poor results three days prior! That would destroy both the conference's and Andreas' international credibility and reputation. So no, I find it VERY difficult to envision those two scenarios at Friday's HCA meeting. (but I reserve the right to the 0.001%)·17 t sittenCurasight is accustomed to presenting their quarterly report in collaboration with HC Andersen Capital, so I imagine it will be a non event, where they (again) emphasize that everything is going according to plan. Finally, there's a Q&A session from the investors, where Ulrich and Andreas confidently repeat that everything looks rosy. Neither more nor less...which is also quite sufficient... :)
- ·22.5.CURIUM AGREEMENT CHANGES EVERYTHING FOR CURASIGHT ☢️🔥 The partnership agreement with Curium gives Curasight direct access to existing global radiopharma infrastructure. Curium contributes not only with capital, but also with regulatory experience, global commercialization as well as production and distribution. The agreement includes milestone payments of up to 70 mio USD and double-digit royalties. In addition, Curium finances the entire uTRACE Phase II-program. Curium has the largest ownership stake in Curasight at 20%. This sends a significant signal about how much potential they see in the platform. The agreement with Curium is a huge advantage because Curasight does not start from scratch! 🔥 They are already directly connected to an existing global setup within isotopes, production, GMP, regulatory processes and distribution - something that takes many years and enormous investments to build up. And that is precisely what the market is increasingly starting to see. Theranostics is no longer just about strong biology and clinical data. In radiopharma, infrastructure has become at least as important. Isotopes are produced in relatively few places in the world, decay quickly and must be produced, transported and delivered almost in real-time. The entire value chain is complex, expensive and extremely difficult to scale quickly. BIG PHARMA POSITIONS ITSELF AGGRESSIVELY ☢️ The radiopharma market is expected to grow massively in the coming 5-10 years, and infrastructure can potentially become a real bottleneck. So strong data is therefore not enough if one cannot simultaneously produce and deliver the treatments globally. Already now, Novartis has started to experience capacity and delivery problems with both Pluvicto and Lutathera. That says a lot about how pressured the market is already starting to become. That is also why Big Pharma and the largest radiopharma companies are positioning themselves so aggressively right now. The battle is no longer just about who has the best data. RADIOPHARMA GOES FROM “SCIENCE” TO “INDUSTRIAL WAR” 🏭 The battle is not just about who has the best data. It is also about who can most quickly secure isotopes, production and global scaling. And this is precisely where the Curium agreement becomes so important. Curasight does not just get a partner. They get access to a large existing industrial engine in a market where infrastructure will probably become a major bottleneck in the coming years. This makes the platform significantly more attractive because a potential partner or buyer does not have to start building the entire infrastructure from scratch. As the theranostics market grows, it becomes crucial who can industrialize and scale globally. Big Pharma does not only get access to the uPAR platform and the data. They also get access to an existing setup for production, isotopes and global distribution from day one! And precisely that fact makes Curasight much more attractive in a future partnership or acquisition scenario! 🎯
- ·22.5.A minor detail, but Curasight has updated their "About us" subpage: The wording is more commercially oriented and emphasizes Utreat as Next-Gen. https://www.curasight.com/about-us/ (for comparison; the "About us" subpage from February 2026: https://web.archive.org/web/20260207020421/https://www.curasight.com/about-us/ Can this be read as optimization in connection with the upcoming SNMMI conference?·3 päivää sitten · MuokattuThey are redefining themselves as a clinical radiopharma platform with a theranostics focus! Great, we are truly on the right track! It will be interesting to see if, in connection with the Q1 report next week, which is a couple of days before the SNMMI conference, an FBM comes, so Andreas can talk about new uTREAT data at SNMMI. I find it very difficult to see Andreas going on the big international stage with old data!·3 päivää sittenI asked Ulrich on April 16th at the investor seminar if there would be ongoing data from uTreat before they release Topline results. And the answer was that they expected an update before Topline. So it could actually be quite likely and good timing here before the conference.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Spotlight Stock Market DK
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 428 | NRD | AVA | ||
| 1 025 | NRD | AVA | ||
| 475 | NRD | DDB | ||
| 1 500 | NRD | NRD | ||
| 1 115 | NRD | SSWM |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Välittäjätilasto
Ostaneet eniten
| Välittäjä | Ostettu | Myyty | Netto | Sisäinen |
|---|---|---|---|---|
| Nordnet Bank AB | 15 709 | 7 798 | +7 911 | 3 769 |
| Danske Bank A/S | 4 324 | 975 | +3 349 | 0 |
| Skandinaviska Enskilda Banken AB | 320 | 0 | +320 | 0 |
| Carnegie Investment Bank AB | 210 | 0 | +210 | 0 |
| SSW Market Making GmbH | 1 579 | 4 810 | −3 231 | 0 |
| Avanza Bank AB | 1 308 | 4 693 | −3 385 | 0 |
Myyneet eniten
| Välittäjä | Ostettu | Myyty | Netto | Sisäinen |
|---|---|---|---|---|
| Nordea Bank Abp | 4 671 | 9 845 | −5 174 | 1 543 |
| Avanza Bank AB | 1 308 | 4 693 | −3 385 | 0 |
| SSW Market Making GmbH | 1 579 | 4 810 | −3 231 | 0 |
| Carnegie Investment Bank AB | 210 | 0 | +210 | 0 |
| Skandinaviska Enskilda Banken AB | 320 | 0 | +320 | 0 |
| Danske Bank A/S | 4 324 | 975 | +3 349 | 0 |
Asiakkaat katsoivat myös
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q1 -tulosraportti 29.5. | 3 päivää |
| Menneet tapahtumat | ||
|---|---|---|
2025 Q4 -tulosraportti 26.2. | ||
2025 Q3 -tulosraportti 1.12.2025 | ||
2025 Q2 -tulosraportti 28.8.2025 | ||
2025 Q1 -tulosraportti 25.4.2025 | ||
2024 Q4 -tulosraportti 27.2.2025 |
2025 Q4 -tulosraportti
89 päivää sitten
‧39 min
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q1 -tulosraportti 29.5. | 3 päivää |
| Menneet tapahtumat | ||
|---|---|---|
2025 Q4 -tulosraportti 26.2. | ||
2025 Q3 -tulosraportti 1.12.2025 | ||
2025 Q2 -tulosraportti 28.8.2025 | ||
2025 Q1 -tulosraportti 25.4.2025 | ||
2024 Q4 -tulosraportti 27.2.2025 |
Foorumi
Liity keskusteluun Nordnet Socialissa
Kirjaudu
- ·1 päivä sittenWhat do people say - what are your expectations or hopes regarding the earnings report - a big increase, a smaller decrease or something else???
- ·2 päivää sittenExciting·1 päivä sitten · MuokattuWell, in principle, anything is possible. And when we don't have exact knowledge, it must rely on probabilities. So my 'certainty'= 99.999% This is primarily because HCA's Friday meeting is a regulatory necessity, held to give the market an update before the international spotlight turns on SNMMI, where Andreas presents on Tuesday. Had the data been bad or delayed, this meeting would never have been arranged the day before the conference starts..! That would be shooting oneself in the foot. If data is delayed, they would have had ample time to announce it to the market, which they would also be obliged to do. If data is not good enough to confirm that Curasight has a real theranostics-platform, which consists of both the diagnostic AND the therapeutic part, then it would be pure madness for Andreas to participate.. And SNMMI would never invite a top-tier researcher if his own flagship (uTREAT) had just proven to fail or deliver poor results three days prior! That would destroy both the conference's and Andreas' international credibility and reputation. So no, I find it VERY difficult to envision those two scenarios at Friday's HCA meeting. (but I reserve the right to the 0.001%)·17 t sittenCurasight is accustomed to presenting their quarterly report in collaboration with HC Andersen Capital, so I imagine it will be a non event, where they (again) emphasize that everything is going according to plan. Finally, there's a Q&A session from the investors, where Ulrich and Andreas confidently repeat that everything looks rosy. Neither more nor less...which is also quite sufficient... :)
- ·22.5.CURIUM AGREEMENT CHANGES EVERYTHING FOR CURASIGHT ☢️🔥 The partnership agreement with Curium gives Curasight direct access to existing global radiopharma infrastructure. Curium contributes not only with capital, but also with regulatory experience, global commercialization as well as production and distribution. The agreement includes milestone payments of up to 70 mio USD and double-digit royalties. In addition, Curium finances the entire uTRACE Phase II-program. Curium has the largest ownership stake in Curasight at 20%. This sends a significant signal about how much potential they see in the platform. The agreement with Curium is a huge advantage because Curasight does not start from scratch! 🔥 They are already directly connected to an existing global setup within isotopes, production, GMP, regulatory processes and distribution - something that takes many years and enormous investments to build up. And that is precisely what the market is increasingly starting to see. Theranostics is no longer just about strong biology and clinical data. In radiopharma, infrastructure has become at least as important. Isotopes are produced in relatively few places in the world, decay quickly and must be produced, transported and delivered almost in real-time. The entire value chain is complex, expensive and extremely difficult to scale quickly. BIG PHARMA POSITIONS ITSELF AGGRESSIVELY ☢️ The radiopharma market is expected to grow massively in the coming 5-10 years, and infrastructure can potentially become a real bottleneck. So strong data is therefore not enough if one cannot simultaneously produce and deliver the treatments globally. Already now, Novartis has started to experience capacity and delivery problems with both Pluvicto and Lutathera. That says a lot about how pressured the market is already starting to become. That is also why Big Pharma and the largest radiopharma companies are positioning themselves so aggressively right now. The battle is no longer just about who has the best data. RADIOPHARMA GOES FROM “SCIENCE” TO “INDUSTRIAL WAR” 🏭 The battle is not just about who has the best data. It is also about who can most quickly secure isotopes, production and global scaling. And this is precisely where the Curium agreement becomes so important. Curasight does not just get a partner. They get access to a large existing industrial engine in a market where infrastructure will probably become a major bottleneck in the coming years. This makes the platform significantly more attractive because a potential partner or buyer does not have to start building the entire infrastructure from scratch. As the theranostics market grows, it becomes crucial who can industrialize and scale globally. Big Pharma does not only get access to the uPAR platform and the data. They also get access to an existing setup for production, isotopes and global distribution from day one! And precisely that fact makes Curasight much more attractive in a future partnership or acquisition scenario! 🎯
- ·22.5.A minor detail, but Curasight has updated their "About us" subpage: The wording is more commercially oriented and emphasizes Utreat as Next-Gen. https://www.curasight.com/about-us/ (for comparison; the "About us" subpage from February 2026: https://web.archive.org/web/20260207020421/https://www.curasight.com/about-us/ Can this be read as optimization in connection with the upcoming SNMMI conference?·3 päivää sitten · MuokattuThey are redefining themselves as a clinical radiopharma platform with a theranostics focus! Great, we are truly on the right track! It will be interesting to see if, in connection with the Q1 report next week, which is a couple of days before the SNMMI conference, an FBM comes, so Andreas can talk about new uTREAT data at SNMMI. I find it very difficult to see Andreas going on the big international stage with old data!·3 päivää sittenI asked Ulrich on April 16th at the investor seminar if there would be ongoing data from uTreat before they release Topline results. And the answer was that they expected an update before Topline. So it could actually be quite likely and good timing here before the conference.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Spotlight Stock Market DK
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 428 | NRD | AVA | ||
| 1 025 | NRD | AVA | ||
| 475 | NRD | DDB | ||
| 1 500 | NRD | NRD | ||
| 1 115 | NRD | SSWM |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Välittäjätilasto
Ostaneet eniten
| Välittäjä | Ostettu | Myyty | Netto | Sisäinen |
|---|---|---|---|---|
| Nordnet Bank AB | 15 709 | 7 798 | +7 911 | 3 769 |
| Danske Bank A/S | 4 324 | 975 | +3 349 | 0 |
| Skandinaviska Enskilda Banken AB | 320 | 0 | +320 | 0 |
| Carnegie Investment Bank AB | 210 | 0 | +210 | 0 |
| SSW Market Making GmbH | 1 579 | 4 810 | −3 231 | 0 |
| Avanza Bank AB | 1 308 | 4 693 | −3 385 | 0 |
Myyneet eniten
| Välittäjä | Ostettu | Myyty | Netto | Sisäinen |
|---|---|---|---|---|
| Nordea Bank Abp | 4 671 | 9 845 | −5 174 | 1 543 |
| Avanza Bank AB | 1 308 | 4 693 | −3 385 | 0 |
| SSW Market Making GmbH | 1 579 | 4 810 | −3 231 | 0 |
| Carnegie Investment Bank AB | 210 | 0 | +210 | 0 |
| Skandinaviska Enskilda Banken AB | 320 | 0 | +320 | 0 |
| Danske Bank A/S | 4 324 | 975 | +3 349 | 0 |